This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| NovaSeq | |
|---|---|
| Name | NovaSeq |
| Developer | Illumina |
| Release | 2017 |
| Type | DNA sequencing platform |
| Medium | Flow cell |
| Applications | Whole-genome sequencing, exome sequencing, transcriptomics |
| Throughput | Up to terabases per run |
| Read lengths | Up to 2×250 bp (platform-dependent) |
| Connectivity | Local compute, cloud pipelines |
NovaSeq is a high-throughput DNA sequencing platform developed for large-scale genomics, population studies, clinical research, and translational science. The system integrates patterned flow-cell technology, two-color chemistry, and scalable instrument configurations intended to increase yield and reduce per-base cost for projects such as population genetics, cancer genomics, and microbial surveillance. It is commonly deployed in core facilities, pharmaceutical pipelines, and consortium projects that require massive parallel sequencing capacity.
NovaSeq was introduced by Illumina as part of a lineage that includes predecessors and contemporaries such as the HiSeq X Ten, HiSeq 4000, MiSeq, NextSeq, and NovaSeq X families. The platform targets large projects from national biobanks to translational networks like the 100,000 Genomes Project, All of Us Research Program, and research consortia involving institutions such as the Broad Institute, Wellcome Sanger Institute, and European Bioinformatics Institute. NovaSeq systems are sold to universities, genomics centers, biotechnology companies including Genentech and Regeneron, and public health agencies such as the Centers for Disease Control and Prevention.
NovaSeq architecture combines patterned flow cells similar to those used in HiSeq X Ten with two-color reversible terminator chemistry that evolved from earlier methods featured on platforms like HiSeq 2500. The instrument utilizes advanced optics and high-density clustering enabled by surface chemistry innovations originally developed alongside partners including Stanford University and commercial collaborators. Key components include fluidics modules, imaging systems, and on-board control electronics modeled on platforms used in large-scale sequencing centers at institutions like NHGRI-funded cores and private laboratories at Illumina Cambridge. Instrument variants offer different throughput capacities and run-time trade-offs to accommodate projects from clinical panels to whole-genome sequencing used by groups such as UK Biobank.
Typical NovaSeq workflows begin with library preparation workflows standardized by vendors and research groups at organizations like New England Biolabs and protocols adopted by clinical networks such as Genomics England. Applications span whole-genome sequencing for population cohorts, exome and targeted panels for oncology studies performed at centers like Memorial Sloan Kettering Cancer Center, RNA-seq for transcriptome profiling in consortia such as the ENCODE Project, and metagenomics for surveillance used by agencies including World Health Organization collaborators. Sample multiplexing strategies using unique dual indices are common in studies coordinated by institutions like Harvard Medical School and sequencing centers at Broad Institute and Sanger Institute.
NovaSeq variants deliver throughput measured in hundreds of gigabases to multiple terabases per run, positioning the platform for projects similar in scale to the 1000 Genomes Project and national sequencing efforts led by entities like Genomics England and All of Us Research Program. Run times vary by configuration and read length, with trade-offs between rapid turnaround favored in clinical labs at institutions like Mayo Clinic and maximal yield sought by population genomics centers such as deCODE genetics. Performance metrics include cluster density, Q-score distributions, and percent aligned reads evaluated routinely by sequencing cores at universities like University of Cambridge and commercial service providers including BGI partners.
Data generated by NovaSeq is processed using base-calling and demultiplexing software commonly deployed at facilities like European Bioinformatics Institute and the Broad Institute. Downstream analysis pipelines integrate tools developed by communities around projects including GATK from the Broad Institute, variant interpretation efforts at ClinVar and ClinGen, and RNA quantification methods used by ENCODE. High-throughput centers rely on compute infrastructures offered by cloud providers such as Amazon Web Services and Google Cloud Platform to scale alignment (e.g., using BWA), variant calling, and annotation for studies overseen by institutions like National Institutes of Health and pharmaceutical groups including Pfizer.
Compared with predecessors like HiSeq 2500 and contemporaries such as NextSeq 2000, NovaSeq emphasizes maximum throughput and cost per Gb efficiency, while instruments like MiSeq prioritize turnaround and small-batch flexibility for clinical and microbiology labs like those at CDC branches. The platform’s patterned flow-cell approach parallels the strategy used in high-capacity systems like HiSeq X Ten but differs from single-flow-cell designs favored in benchtop instruments used by academic laboratories at Johns Hopkins University. System selection often balances project scale and operational contexts found at centers including Sanger Institute and pharmaceutical sequencing facilities at Roche.
Challenges associated with NovaSeq deployments include initial capital costs for instruments and infrastructure encountered by university cores such as those at University of California, San Francisco, demand for large sample batching to achieve cost efficiency observed in population projects like UK Biobank, and technical artifacts such as index hopping and low-diversity handling that have been studied by groups at Broad Institute and Illumina Technical Note contributors. Operational considerations include supply chain dependencies for consumables affecting public health responses coordinated by World Health Organization partners, and bioinformatics scaling needs that require investments in resources used by centers like European Bioinformatics Institute.
Category:DNA sequencing platforms